Mainz Biomed Analyst Ratings
Mainz Biomed Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/21/2023 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 11/20/2023 | 300% | HC Wainwright & Co. | $9 → $5 | Maintains | Buy |
| 09/26/2023 | 620% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 09/22/2023 | 620% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 09/14/2023 | 620% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/22/2023 | 620% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 460% | HC Wainwright & Co. | $10 → $7 | Reiterates | Buy → Buy |
| 06/01/2023 | 700% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/18/2023 | 860% | Cantor Fitzgerald | $15 → $12 | Maintains | Overweight |
| 04/27/2023 | 700% | HC Wainwright & Co. | $25 → $10 | Maintains | Buy |
| 03/30/2023 | 1900% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/16/2023 | 1900% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/10/2023 | 780% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
| 10/25/2022 | 1100% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 06/21/2022 | 1900% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/21/2023 | — | 坎託·菲茨傑拉德 | 降級 | 超重 → 中性 | |
| 11/20/2023 | 300% | HC Wainwright & Co. | 9 美元 → 5 美元 | 維護 | 購買 |
| 09/26/2023 | 620% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 09/22/2023 | 620% | HC Wainwright & Co. | 7 美元 → 9 美元 | 維護 | 購買 |
| 09/14/2023 | 620% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | 620% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 08/18/2023 | 460% | HC Wainwright & Co. | 10 美元 → 7 美元 | 重申 | 購買 → 購買 |
| 06/01/2023 | 700% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 05/18/2023 | 860% | 坎託·菲茨傑拉德 | 15 美元 → 12 美元 | 維護 | 超重 |
| 04/27/2023 | 700% | HC Wainwright & Co. | 25 美元 → 10 美元 | 維護 | 購買 |
| 03/30/2023 | 1900% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
| 02/16/2023 | 1900% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
| 02/10/2023 | 780% | JonesTrading | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/25/2022 | 1100% | 坎託·菲茨傑拉德 | → 15 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 6 月 21 日 | 1900% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Mainz Biomed (MYNZ)?
美因茲生物醫學（MYNZ）的目標價格是多少？
The latest price target for Mainz Biomed (NASDAQ: MYNZ) was reported by Cantor Fitzgerald on November 21, 2023. The analyst firm set a price target for $0.00 expecting MYNZ to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年11月21日公佈了美因茲生物醫學（納斯達克股票代碼：MYNZ）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計MYNZ將在12個月內跌至0.00美元（可能下跌-100.00％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for Mainz Biomed (MYNZ)?
美因茲生物醫學（MYNZ）的最新分析師評級是多少？
The latest analyst rating for Mainz Biomed (NASDAQ: MYNZ) was provided by Cantor Fitzgerald, and Mainz Biomed downgraded their neutral rating.
美因茲生物醫學（納斯達克股票代碼：MYNZ）的最新分析師評級由坎託·菲茨傑拉德提供，美因茲生物醫學下調了中性評級。
When is the next analyst rating going to be posted or updated for Mainz Biomed (MYNZ)?
美因茲生物醫學（MYNZ）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on November 21, 2023 so you should expect the next rating to be made available sometime around November 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與美因茲生物醫學的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。美因茲生物醫學的最新評級是在2023年11月21日提交的，因此您應該預計下一個評級將在2024年11月21日左右公佈。
Is the Analyst Rating Mainz Biomed (MYNZ) correct?
分析師評級美因茲生物醫學（MYNZ）是否正確？
While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a downgraded with a price target of $0.00 to $0.00. The current price Mainz Biomed (MYNZ) is trading at is $1.25, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的美因茲生物醫學（MYNZ）評級下調，目標股價爲0.00美元至0.00美元。美因茲生物醫學（MYNZ）目前的交易價格爲1.25美元，超出了分析師的預測區間。